{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:41:42Z","timestamp":1772822502713,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014620","name":"Micropalaeontological Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lungcan.2025.108716","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:37:49Z","timestamp":1755808669000},"page":"108716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-9878","authenticated-orcid":false,"given":"Hai-Yan","family":"Tu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-597X","authenticated-orcid":false,"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junke","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongde","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Min","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-0258","authenticated-orcid":false,"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108716_b0005","unstructured":"International Agency for Research on Cancer, Cancer TODAY, Data version: Globocan 2022 -08.02.2024, https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&types=1. (accessed 14 March 2025)."},{"issue":"13","key":"10.1016\/j.lungcan.2025.108716_b0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.lungcan.2025.108716_b0015","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics, Surveillance Research Program, National Cancer Institute, https:\/\/seer.cancer.gov\/statistics-network\/explorer\/, (accessed 14 March 2025)."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108716_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176329","article-title":"Targeted therapies in early stage NSCLC: hype or hope?","volume":"21","author":"Friedlaender","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117333","article-title":"Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13000-019-0789-1","article-title":"Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland","volume":"14","author":"Grosse","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2025.108716_b0035","unstructured":"Chinese Expert Group on Early Diagnosis and Treatment of Lung Cancer, China Lung Oncology Group, China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version), Zhongguo Fei Ai Za Zhi 26(1) (2023) 1-9, doi: 10.3779\/j.issn.1009-3419.2023.102.10."},{"issue":"e081674","key":"10.1016\/j.lungcan.2025.108716_b0040","article-title":"Lung cancer screening in people who have never smoked: lessons from East Asia","volume":"388","author":"Welch","year":"2025","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.lungcan.2025.108716_b0045","doi-asserted-by":"crossref","unstructured":"G.C. Chang, C.H. Chiu, C.J. Yu, Y.C. Chang, Y.H. Chang, K.H. Hsu, Y.C. Wu, C.Y. Chen, H.H. Hsu, M.T. Wu, et al., Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study, Lancet Respir. Med. 12(2) (2024) 141\u2013152, doi:10.1016\/S2213-2600(23)00338-7.","DOI":"10.1016\/S2213-2600(23)00338-7"},{"key":"10.1016\/j.lungcan.2025.108716_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2018.05.020","article-title":"Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer","volume":"122","author":"Chaft","year":"2018","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108716_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081949","article-title":"Analysis of molecular biomarkers in resected early-stage non-small cells lung cancer: a narrative review","volume":"14","author":"Gallina","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108716_b0060","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1245\/s10434-020-09276-x","article-title":"Targeted next-generation sequencing analysis for recurrence in early-stage lung adenocarcinoma","volume":"28","author":"Kim","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0065","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.21037\/jtd.2018.05.131","article-title":"Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma","volume":"10","author":"Shin","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0070","article-title":"Alectinib versus crizotinib in asian patients with treatment-naive advanced ALK-positive NSCLC: five-year update from the phase 3 ALESIA study","volume":"5","author":"Zhou","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0075","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1038\/s41598-023-34397-0","article-title":"A retrospective study of postoperative targeted therapy in ALK-positive lung cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0080","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10308","key":"10.1016\/j.lungcan.2025.108716_b0085","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0095","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.21.01729","article-title":"Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT)","volume":"40","author":"Tada","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108716_b0105","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108716_b0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0120","unstructured":"National Comprehensive Cancer Network, NCCN guidelines version 3.2025, non-small cell lung cancer, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf, (assessed 14 March 2025)."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108716_b0125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"key":"#cr-split#-10.1016\/j.lungcan.2025.108716_b0130.1","doi-asserted-by":"crossref","unstructured":"N. Health Commission Of The People's Republic Of China, National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version), Chin. J. Cancer Res. 34","DOI":"10.21147\/j.issn.1000-9604.2022.03.03"},{"key":"#cr-split#-10.1016\/j.lungcan.2025.108716_b0130.2","doi-asserted-by":"crossref","unstructured":"(3) (2022) 176-206, doi: 10.21147\/j.issn.1000-9604.2022.03.03.","DOI":"10.21147\/j.issn.1000-9604.2022.03.03"},{"key":"10.1016\/j.lungcan.2025.108716_b0135","unstructured":"Guidelines Working Committee of Chinese Society of Clinical Oncology, Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Non-Small Cell Lung Cancer (2024 version), Pub Date: 2024-04-01 Publisher: People's Medical Publishing House, ISBN 978-7-117-36159-0."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.lungcan.2025.108716_b0145","unstructured":"Group. O L O E W. Oxford centre for evidence-based medicine: Levels of evidence, https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009 (assessed 14 March 2025)."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ijc.33215","article-title":"Category of evidence and consensus underlying national comprehensive cancer network guidelines: is there evidence of progress?","volume":"148","author":"Desai","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2025.108716_b0155","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2025.108716_b0165","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10459","key":"10.1016\/j.lungcan.2025.108716_b0170","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.lungcan.2025.108716_b0175","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108716_b0180","doi-asserted-by":"crossref","unstructured":"J. He, M. Tsuboi, W. Weder, K.N. Chen, M.J. Hochmair, J.Y. Shih, S.Y. Lee, K.Y. Lee, N.V. Nhung, S. Saeteng, et al., Neoadjuvant osimertinib for resectableEGFR-mutated non-small cell lung cancer, J. Clin. Oncol. (JCO2500883) (2025), 2025, doi:10.1200\/JCO-25-00883.","DOI":"10.1200\/JCO-25-00883"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108716_b0185","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0190","series-title":"103rd Annual Meeting of the American Association for Thoracic Surgery","article-title":"Induction ALK-TIKs for stage III non-small cell lung cancer harboring ALK fusion: a single-center experience with 3-year follow-up","author":"Zhang","year":"2023"},{"key":"10.1016\/j.lungcan.2025.108716_b0195","doi-asserted-by":"crossref","unstructured":"J.M. Lee, E.M. Toloza, H.I. Pass, B.E. Johnson, J.V. Heymach, L. Sholl, A. Saqi, W.D. Travis, I. Wistuba, J. Lin, et al., P2.01-06 NAUTIKA1 study: preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC, J. Thorac. Oncol. 18(11) (2023) S297-S298, doi: 10.1016\/j.jtho.2023.09.511.","DOI":"10.1016\/j.jtho.2023.09.511"},{"key":"10.1016\/j.lungcan.2025.108716_b0200","unstructured":"A. Molecular Pathology Collaboration Group of Tumor Pathology Committee of China Anti-Cancer, O. Chinese Medical Association Chinese Society of, C. Pathology Quality Control, [Expert consensus on clinical practice of fusion genes detection in non-small cell lung cancer in China (2023 version)], Zhonghua Bing Li Xue Za Zhi 52(6) (2023) 565-573,doi: 10.3760\/cma.j.cn112151-20221111-00946."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108716_b0205","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1634\/theoncologist.2017-0178","article-title":"ALK fusion detection in circulating free DNA: finding an important needle in the haystack","volume":"22","author":"Mooradian","year":"2017","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.lungcan.2025.108716_b0210","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108716_b0215","doi-asserted-by":"crossref","unstructured":"J. Jee, E.S. Lebow, R. Yeh, J.P. Das, A. Namakydoust, P.K. Paik, J.E. Chaft, G. Jayakumaran, A. Rose Brannon, R. Benayed, et al., Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer, Nat. Med. 28(11) (2022) 2353\u20132363, doi: 10.1038\/s41591-022-02047-z.","DOI":"10.1038\/s41591-022-02047-z"},{"key":"10.1016\/j.lungcan.2025.108716_b0220","doi-asserted-by":"crossref","unstructured":"W. Li, J. Zhang, Z. Wang, L. Li, J. Ma, X. Zhou, J. Wang, Z. Liang, J. Ying, R.s. Experts from the, Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group, J. Natl. Cancer Cent. 1(4) (2021) 123-131, doi: 10.1016\/j.jncc.2021.07.005.","DOI":"10.1016\/j.jncc.2021.07.005"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e318274a83e","article-title":"Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent","volume":"8","author":"Conklin","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0230","unstructured":"P. Chinese Society of, C. Pathology Quality Control, O. Chinese Medical Association Chinese Society of, C. China Anti-cancer Association Chinese Society of Lung, G. Chinese Thoracic Oncology, [Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China], Zhonghua Bing Li Xue Za Zhi 50(4) (2021) 323-332, doi: 10.3760\/cma.j.cn112151-20201220-00945."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0235","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cac2.12593","article-title":"Real-world data on ALK rearrangement test in chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study","volume":"44","author":"Li","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.lungcan.2025.108716_b0240","article-title":"Disease characteristics and treatment outcomes in patients with resected early-stage ALK+ NSCLC from ALINA, a phase III randomized trial of adjuvant alectinib vs. chemotherapy","author":"Wu","year":"2024","journal-title":"104th American Association for Thoracic Surgery (AATS) Annual Meeting"},{"issue":"21","key":"10.1016\/j.lungcan.2025.108716_b0245","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0250","doi-asserted-by":"crossref","unstructured":"N.M.-a.C. Group, Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data, Lancet 383 (9928) (2014) 1561-71, doi: 10.1016\/S0140-6736(13)62159-5.","DOI":"10.1016\/S0140-6736(13)62159-5"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC","volume":"17","author":"Wu","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103929","article-title":"Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors","volume":"184","author":"Ferrara","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0265","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","article-title":"Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial","volume":"6","author":"Wang","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0270","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"26","key":"10.1016\/j.lungcan.2025.108716_b0275","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0280","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108716_b0285","doi-asserted-by":"crossref","first-page":"10041","DOI":"10.1007\/s00432-023-04924-7","article-title":"TP53 or CDKN2A\/B covariation in ALK\/RET\/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis","volume":"149","author":"Jiang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC","volume":"19","author":"Lara-Mejia","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0295","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx380.032","article-title":"Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: results of the network genomic medicine","volume":"28","author":"Riedel","year":"2017","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0300","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108716_b0305","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1200\/JCO.2023.41.16_suppl.9029","article-title":"Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC","volume":"41","author":"Parikh","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0310","doi-asserted-by":"crossref","first-page":"S775","DOI":"10.1016\/j.annonc.2024.08.1265","article-title":"1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)","volume":"35","author":"Solomon","year":"2024","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106668","article-title":"Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 chinese patients","volume":"9","author":"Zhu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2025.108716_b0320","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2018.01.004","article-title":"Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: the effect of postoperative adjuvant chemotherapy","volume":"117","author":"Park","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108716_b0325","unstructured":"J. Li, Risk factor of brain metastases and its influence on patient prognosis after complete resection of non-small cell lung cancer, Am. J. Transl. Res. 14(1) (2022) 406-413, PMID: 35173859; PMCID: PMC8829628."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.18.00131","article-title":"SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Pennell","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.lungcan.2025.108716_b0335","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0340","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0345","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7150\/jca.99319","article-title":"Third generation vs first generation EGFR-TKIs in the first line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a meta-analysis based on randomized controlled trials","volume":"16","author":"Hu","year":"2025","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108716_b0350","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108716_b0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40364-022-00444-7","article-title":"Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives","volume":"11","author":"Godoy","year":"2023","journal-title":"Biomark. Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0360","doi-asserted-by":"crossref","first-page":"S545","DOI":"10.1016\/j.jtho.2024.09.1009","article-title":"EP.07C.13 aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I NSCLC with multiple high-risk factors","volume":"19","author":"Wu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0365","doi-asserted-by":"crossref","unstructured":"R. Geng, Y. Chen, J. Miao, H. Liu, Y. Qin, Z. Han, S. Li, Y. Guan, H. Wu, Y. Zhao, et al., MA15.13 furmonertinib as adjuvant therapy for completely resected stage IA with high-risk factors and IB NSCLC patients with EGFR mutations, J. Thorac. Oncol. 19(10) (2024) S120-S121,doi: 10.1016\/j.jtho.2024.09.216.","DOI":"10.1016\/j.jtho.2024.09.216"},{"key":"10.1016\/j.lungcan.2025.108716_b0370","doi-asserted-by":"crossref","unstructured":"Y. Tsutani, J.W. Goldman, S. Dacic, Y. Yatabe, M. Majem, X. Huang, A. Chen, T. van der Gronde, J. He, Adjuvant osimertinib vs. placebo in completely resected stage IA2-IA3 EGFR-mutated NSCLC: ADAURA2, Clin. Lung Cancer 24(4) (2023) 376-380,doi: 10.1016\/j.cllc.2023.02.002.","DOI":"10.1016\/j.cllc.2023.02.002"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0375","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jtho.2018.10.002","article-title":"Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the japanese joint committee of lung cancer registry database in 2010","volume":"14","author":"Okami","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0380","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/icvts\/ivs450","article-title":"Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction\/adjuvant chemotherapy","volume":"16","author":"Saisho","year":"2013","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0385","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1378\/chest.12-1717","article-title":"Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer","volume":"143","author":"Shimada","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0390","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ejcts\/ezu227","article-title":"Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer","volume":"47","author":"Takenaka","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108716_b0395","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1111\/1759-7714.13669","article-title":"Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure","volume":"11","author":"Sonoda","year":"2020","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0400","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jtho.2018.11.020","article-title":"The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104)","volume":"14","author":"Xu","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108716_b0405","first-page":"523","article-title":"Non-small cell lung cancer lung metastasis? or the second (and more) of primary lung cancer \u2013 key concepts influencing treatment strategies","volume":"17","author":"Chen","year":"2014","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"18","key":"10.1016\/j.lungcan.2025.108716_b0410","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108716_b0415","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"PNAS"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108716_b0420","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108716_b0425","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/JTO.0b013e3181cd3345","article-title":"Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials","volume":"5","author":"Song","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0430","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.athoracsur.2018.11.024","article-title":"The optimal treatment for stage IIIA-N2 non-small cell lung cancer: a network meta-analysis","volume":"107","author":"Zhao","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2025.108716_b0435","doi-asserted-by":"crossref","unstructured":"M. Provencio, E. Nadal, A. Insa, M.R. Garcia-Campelo, J. Casal-Rubio, M. Domine, M. Majem, D. Rodriguez-Abreu, A. Martinez-Marti, J. De Castro Carpeno, et al., Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial, Lancet Oncol. 21(11) (2020) 1413\u20131422, doi: 10.1016\/S1470-2045(20)30453-8.","DOI":"10.1016\/S1470-2045(20)30453-8"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108716_b0440","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108716_b0445","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108716_b0450","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2025.108716_b0455","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0460","doi-asserted-by":"crossref","unstructured":"W.Z. Zhong, C. Zhang, Y. Yang, J. Yang, Q. Zhou, Q. Zhong, W. Liang, Z. Chen, Y. Wu, P3.08F.01 interim analysis of a phase 2 prospective trial of induction lorlatinib in locally advanced ALK-positive NSCLC (LORIN), J. Thorac. Oncol. 19(10) (2024) S337\u2013S338, doi: 10.1016\/j.jtho.2024.09.607.","DOI":"10.1016\/j.jtho.2024.09.607"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108716_b0465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0470","unstructured":"N.Q.C.C.f.C. Expert Committee on Quality Control of Lung Cancer, [Expert consensus on the pathological evaluation of neoadjuvant therapy efficacy for non-small cell lung cancer], Zhonghua Bing Li Xue Za Zhi 50(9) (2021) 1002\u20131007, doi: 10.3760\/cma.j.cn112151-20210429-00335."},{"issue":"10089","key":"10.1016\/j.lungcan.2025.108716_b0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108716_b0480","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","article-title":"Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives","volume":"18","author":"Lee","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108716_b0485","article-title":"ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma","volume":"107215","author":"Gallina","year":"2023","journal-title":"Lung Cancer 180"},{"key":"10.1016\/j.lungcan.2025.108716_b0490","doi-asserted-by":"crossref","unstructured":"J. Costa, A. Membrino, C. Zanchetta, S. Rizzato, F. Cortiula, C. Rossetto, G. Pelizzari, G. Aprile, M. Macerelli, The role of ctDNA in the management of non-small-cell lung cancer in the AI and NGS era, Int. J. Mol. Sci. 25(24) (2024) 13669, 2024, doi:10.3390\/ijms252413669.","DOI":"10.3390\/ijms252413669"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:56:49Z","timestamp":1772801809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":99,"alternative-id":["S0169500225006087"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108716","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108716"}}